NEW YORK

,

March 12, 2021

/PRNewswire/ —

If you own shares in any of the companies listed above and

would like to discuss our investigations or have any questions concerning

this notice or your rights or interests, please contact:

CONTACT:


Joshua Rubin, Esq.


WeissLaw LLP

1500 Broadway, 16th Floor


New York

, NY  10036

(212) 682-3025

(888) 593-4771


[email protected]

Newtown Lane Marketing, Inc.

(OTC: NTWN)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of

Newtown Lane Marketing, Inc.

(OTC: NTWN) in connection with the company’s proposed merger with Appgate. Under the terms of the merger agreement, NTWN will acquire Appgate through a reverse merger that will result in Appgate becoming a publicly traded company. If you own NTWN shares and wish to discuss this investigation or your rights, please call or visit our website:

https://weisslawllp.com/news/ntwn/

Tilray, Inc.

(NASDAQ: TLRY)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of

Tilray, Inc. (

NASDAQ: TLRY) in connection with the company’s proposed merger with Aphria Inc. (“Aphria”).  Under the terms of the merger agreement, Aphria shareholders will receive 0.8381 TLRY shares for each Aphria share they own. Upon closing, TLRY shareholders will only own approximately 38% of the combined company. If you own TLRY shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:

https://www.weisslawllp.com/tlry/

Cleveland BioLabs, Inc.


(

NASDAQ: CBLI)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of

Cleveland BioLabs, Inc.

(NASDAQ: CBLI) in connection with the proposed merger of the company with privately-held biopharmaceutical company, Cytocom, Inc.  Under the terms of the merger agreement, the two companies will combine their businesses in an all-stock transaction that will result in one newly-combined entity that will continue to trade publicly. If you own CBLI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:


http://www.weisslawllp.com/cbli/

Akers Biosciences, Inc.

(NASDAQ: AKER)

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of

Akers Biosciences, Inc.

(NASDAQ: AKER

)

in connection with the company’s proposed merger with privately-held MyMD Pharmaceuticals, Inc. (“MyMD”). Under the terms of the merger agreement, AKER and MyMD will combine resulting in current MyMD stockholders owning 80% of the combined post-close company, leaving AKER stockholders with a mere 20% of the new entity. If you own AKER shares and wish to discuss this investigation or your rights, please call or visit our website:

https://www.weisslawllp.com/aker

View original content to download multimedia:

http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-ntwn-tlry-cbli-and-aker-shareholders-about-its-ongoing-investigations-301246565.html

SOURCE WeissLaw LLP